HomeQuestion
What are your top takeaways from ASCO GU 2025?
3
6 Answers
Mednet Member
Medical Oncology · Duke University School of Medicine
In terms of practice-informing presentations in prostate cancer here are my top 3:
- GROUQ-PCS 9 trial (Canada, abstract 22). This trial led by Niazi et al tested whether metastasis-directed radiotherapy based on conventional imaging to up to 5 sites provided benefits in delaying rPFS or PSA progressi...
Mednet Member
Medical Oncology · Yale School of Medicine
The one trial that will impact my practice is the COTRIMS trial, which assessed RPLND in stage 2A and non-bulky stage 2B seminoma. Traditionally, stage 2 seminoma has been treated with radiation or with BEP chemotherapy x3 cycles or EP x4 cycles. However, there is recognition that both chemotherapy ...
Mednet Member
Medical Oncology · University of Virginia
Well done trial, clinically meaningful OS benefit
Caveats
- Would b...
Mednet Member
Radiation Oncology · University of British Columbia
My favorites were
- Abstract 308 (middle or high veracyte score predicts benefit of dose escalation).
- Abstract 309 (comparison of 2 trials reveals higher distant metastatic failure rate with a surgical-based approach for high-risk prostate cancer than seen with a radiation-based approach)
- Abstract 20...
Mednet Member
Medical Oncology · University of Minnesota–Masonic Cancer Center
Mednet Member
Medical Oncology · University of Washington School of Medicine
Interesting bladder Ca trials at GU ASCO 2025:
- NIAGARA trial updates
- CheckMate 274 trial updates
- RETAIN-2 trial and also the poster by Ruben Raychaudhuri et al. (aMVAC + pembrolizumab for MIBC with histology subtypes)
- EV-302 updates for 1L metastatic disease
- T-DXd, FGFR inhibitor, TROP2 ADC data ...